<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267056</url>
  </required_header>
  <id_info>
    <org_study_id>Acotec-04</org_study_id>
    <nct_id>NCT03267056</nct_id>
  </id_info>
  <brief_title>AcoArt IV / SFA in China:Drug-eluting Balloon for SFA Angioplasty Evaluation in China</brief_title>
  <official_title>Real-World Registry Assessing the Clinical Use of the Orchid Drug Coated Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry is a prospective, multicenter, single arm post-market real-world registry in&#xD;
      China assessing the clinical use, safety and outcomes of the Orchid 035 DCB Catheter in the&#xD;
      Superficial Femoral Artery (SFA) and Popliteal Arteries (PA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTA is an established alternative to open surgical bypass for the treatment of infrainginual&#xD;
      disease of critical limb ischemia.&#xD;
&#xD;
      DEBs are designed to promote arterial patency by reducing neointimal proliferation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Primary patency of target lesion.</measure>
    <time_frame>12 months</time_frame>
    <description>The primary efficacy end point was primary patency at 12 months following the index procedure, defined as freedom from clinically driven target lesion revascularization and restenosis as determined by a duplex ultrasonography-derived peak systolic velocity ratio of&#xD;
â‰¤2.4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization,target lesion revascularization is defined as any reintervention of artery bypass graft surgery involving the target lesion</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>target lesion revascularization is defined as any reintervention of artery bypass graft surgery involving the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvment in Rutherford stage</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>improvementin Rutherford stage is defined as an upward shift of at least 1 category on Rutherford classification as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in ankle brachial index(ABI)</measure>
    <time_frame>12 months</time_frame>
    <description>change in ankle brachial index(ABI) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success during the operation</measure>
    <time_frame>during the operation</time_frame>
    <description>Device success is defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>DCB arm</arm_group_label>
    <description>drug eluting balloon catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting balloon catheter (trade name: Orchid)</intervention_name>
    <description>use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery</description>
    <arm_group_label>DCB arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with a more than 70% stenosis at femoral and/or popliteal artery meet all the&#xD;
        inclusion and excluison criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Patients with peripheral artery disease (PAD), with Rutherford classification between&#xD;
             2 and 5&#xD;
&#xD;
          -  an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral&#xD;
             artery an /or the popliteal artery&#xD;
&#xD;
          -  Total length of treat lesion(s)is less or equal to 20cm&#xD;
&#xD;
          -  signed Patient informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  plasma Cr level greater than 150 umol/L in patients&#xD;
&#xD;
          -  patients with acute thrombosis requiring lysis or thrombectomy&#xD;
&#xD;
          -  2 or more than 2 stenosis lesions in traget vessel&#xD;
&#xD;
          -  patient with a lysis or an lower limb intervention as a therapy within the last 6&#xD;
             weeks&#xD;
&#xD;
          -  patient requiring intervention in both lower limbs at the same time&#xD;
&#xD;
          -  have &gt;30% residual stenosis or blood-limited dissection after predilation&#xD;
&#xD;
          -  distal outflow through less than one lower leg vessel&#xD;
&#xD;
          -  known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,&#xD;
             etc.&#xD;
&#xD;
          -  patients participating in another clinical trials with interfere with this trial in&#xD;
             the past 3 months&#xD;
&#xD;
          -  pregnancy and lactating woman&#xD;
&#xD;
          -  untreatable bleeding diatheses&#xD;
&#xD;
          -  other diseases, such as cancer, liver disease, or cardiac insufficiency, which may&#xD;
             lead to protocol violations or markedly shorten a patients's life expectancy(less than&#xD;
             1 years)&#xD;
&#xD;
          -  patients unable or unwilling to participate this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yinghua Zou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan central hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin First Center Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Nanjing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

